ESMO 2016: A Therapeutic Update on the Management of Patients with Non-Small Cell Lung Cancer
Potentially practice-changing data from clinical trials in non-small cell lung cancer (NSCLC) were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11 in Copenhagen, Denmark. These data may not only lead to new treatment options but also help clinicians use existing treatment options more effectively. In this video presentation, two leading experts in the management of NSCLC review key results presented at ESMO 2016 and provide insights on how the results may influence practice today.
This activity has been designed to meet the educational needs of pulmonologists, oncologists, and other health care professionals involved in the diagnosis, treatment, or management of patients with NSCLC.
Upon completion of this activity, participants will be able to:
- Discuss molecular screening of NSCLC
- Assess clinical trial data of emerging therapies for the treatment of NSCLC presented at ESMO 2016
- Develop data-driven, individualized treatment plans to improve treatment selection and outcomes for patients with NSCLC
Dr. Corey Langer
University of Pennsylvania, Philadelphia, USA
Dr. Charu Aggarwal
Abramson Cancer Center, Philadelphia, USA
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Corey Langer, MD|
Consultant/Advisor: Abbott, ARIAD Pharmaceuticals, Inc., AstraZeneca, Bayer Pharma AG/Onyx Pharmaceuticals, Inc., Biodesix, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Caris Life Sciences, Celgene Corporation, Clariant, Clovis Oncology, Eli Lilly and Company, Genentech, Inc., ImClone Systems Inc., Novartis AG, Pfizer Inc., Synta
Grant/Research Support: Advantagene, Inc., ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Clovis Oncology, Eli Lilly and Company, Genentech, Inc., GSK group of companies, ImClone Systems Inc., Inovio Pharmaceuticals, Inc., Merck & Co., Inc, Nektar, OSI Pharmaceuticals, Inc., Pfizer Inc.
Charu Aggarwal, MD
Consultant/Advisor: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc.
Speaker's Bureau: Boehringer Ingelheim GmbH, Genentech, Inc., Novartis AG, Pfizer Inc.
Non-faculty: Julie Huang; Sandy Breslow; Alison Kemp; Leah Johnson and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Merck Sharp & Dohme Corp.
Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com. Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica, and Merck Sharp & Dohme Corp. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician